{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:51:02Z","timestamp":1776286262074,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015872","name":"Universit\u00e9 de Lille","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.molmet.2021.101410","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T12:19:54Z","timestamp":1638361194000},"page":"101410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells"],"prefix":"10.1016","volume":"55","author":[{"given":"Anne","family":"Trinh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raeeka","family":"Khamari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-8022","authenticated-orcid":false,"given":"Quentin","family":"Fovez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Turcq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Bouscary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Maboudou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Joncquel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Coiteux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-3245","authenticated-orcid":false,"given":"Nicolas","family":"Germain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Laine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Dekiouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Jean-Pierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Maguer-Satta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Ghesquiere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Idziorek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-2709","authenticated-orcid":false,"given":"Bruno","family":"Quesnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7346-1305","authenticated-orcid":false,"given":"Jerome","family":"Kluza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4663-6800","authenticated-orcid":false,"given":"Philippe","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.molmet.2021.101410_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.molmet.2021.101410_bib2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2021.101410_bib3","series-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","author":"Rea","year":"2018"},{"issue":"2","key":"10.1016\/j.molmet.2021.101410_bib4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1634\/theoncologist.2009-0297","article-title":"Why doesn't imatinib cure chronic myeloid leukemia?","volume":"15","author":"Redner","year":"2010","journal-title":"The Oncologist"},{"issue":"3","key":"10.1016\/j.molmet.2021.101410_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-018-0532-2","article-title":"When to Stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"19","author":"Laneuville","year":"2018","journal-title":"Current Treatment Options in Oncology"},{"key":"10.1016\/j.molmet.2021.101410_bib6","first-page":"283145","article-title":"Integration of mitochondrial targeting for molecular cancer therapeutics","author":"Marchetti","year":"2015","journal-title":"International Journal of Cell Biology"},{"issue":"4","key":"10.1016\/j.molmet.2021.101410_bib7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbagen.2018.01.018","article-title":"Melanoma metabolism contributes to the cellular responses to MAPK\/ERK pathway inhibitors","volume":"1862","author":"Marchetti","year":"2018","journal-title":"Biochimica et Biophysica Acta (BBA) - General Subjects"},{"issue":"3","key":"10.1016\/j.molmet.2021.101410_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41419-018-0340-4","article-title":"Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors","volume":"9","author":"Khamari","year":"2018","journal-title":"Cell Death & Disease"},{"issue":"4","key":"10.1016\/j.molmet.2021.101410_bib9","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2004-03-0849","article-title":"Activation of the PI3K\/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species","volume":"105","author":"Kim","year":"2005","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.molmet.2021.101410_bib10","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1038\/sj.onc.1208461","article-title":"Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.molmet.2021.101410_bib11","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","article-title":"Imatinib (STI571)-Mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells","volume":"10","author":"Gottschalk","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1016\/j.molmet.2021.101410_bib12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.18632\/aging.100734","article-title":"Oncogenic drivers and mitochondrial dependency","volume":"7","author":"Alvarez-Calderon","year":"2015","journal-title":"Aging"},{"issue":"10","key":"10.1016\/j.molmet.2021.101410_bib13","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nature Medicine"},{"issue":"9","key":"10.1016\/j.molmet.2021.101410_bib14","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/sj.leu.2402590","article-title":"Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia","volume":"16","author":"Saudemont","year":"2002","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.molmet.2021.101410_bib15","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1182\/blood-2004-01-0064","article-title":"In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis","volume":"104","author":"Saudemont","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.molmet.2021.101410_bib16","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood-2004-09-3458","article-title":"NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells","volume":"105","author":"Saudemont","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.molmet.2021.101410_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021924","article-title":"Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells","volume":"6","author":"Kluza","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.molmet.2021.101410_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2015.11.020","article-title":"Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells","volume":"371","author":"Shinohara","year":"2016","journal-title":"Cancer Letters"},{"key":"10.1016\/j.molmet.2021.101410_bib19","author":"Jacque","year":"2015"},{"issue":"20","key":"10.1016\/j.molmet.2021.101410_bib20","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2013-03-493163","article-title":"Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia","volume":"122","author":"Willems","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.molmet.2021.101410_bib21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.molmet.2021.101410_bib22","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1172\/JCI30235","article-title":"Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase","volume":"117","author":"Iwamoto","year":"2007","journal-title":"Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/j.molmet.2021.101410_bib23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3324\/haematol.2010.029082","article-title":"Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate","volume":"96","author":"Giuntoli","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.molmet.2021.101410_bib24","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/0008-5472.CAN-06-1627","article-title":"Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1","volume":"67","author":"Saudemont","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.molmet.2021.101410_bib25","author":"Gallipoli","year":"2018"},{"issue":"7","key":"10.1016\/j.molmet.2021.101410_bib26","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discovery"},{"issue":"1","key":"10.1016\/j.molmet.2021.101410_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1172\/JCI38942","article-title":"Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction","volume":"120","author":"Samudio","year":"2010","journal-title":"Journal of Clinical Investigation"},{"issue":"43","key":"10.1016\/j.molmet.2021.101410_bib28","first-page":"E6669","article-title":"ATM\/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia","volume":"113","author":"Gregory","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2021.101410_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2017.09.007","article-title":"Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia","volume":"58","author":"Gregory","year":"2018","journal-title":"Experimental Hematology"},{"issue":"6","key":"10.1016\/j.molmet.2021.101410_bib30","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-14-2146","article-title":"Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations","volume":"21","author":"Alvarez-Calderon","year":"2015","journal-title":"Clinical Cancer Research : An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.molmet.2021.101410_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/leusup.2014.3","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","author":"Eiring","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.molmet.2021.101410_bib32","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/OTT.S106810","article-title":"Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia","volume":"10","author":"Koprivnikar","year":"2017","journal-title":"OncoTargets and Therapy"},{"issue":"12","key":"10.1016\/j.molmet.2021.101410_bib33","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/ncb3278","article-title":"Rethinking glutamine addiction","volume":"17","author":"Krall","year":"2015","journal-title":"Nature Cell Biology"},{"issue":"2","key":"10.1016\/j.molmet.2021.101410_bib34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.molcel.2014.08.018","article-title":"Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion","volume":"56","author":"Zhang","year":"2014","journal-title":"Molecular Cell"},{"issue":"9","key":"10.1016\/j.molmet.2021.101410_bib35","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.leu.2403886","article-title":"Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"19","author":"Lee","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.molmet.2021.101410_bib36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cmet.2017.12.006","article-title":"As extracellular glutamine levels decline, asparagine becomes an essential amino acid","volume":"27","author":"Pavlova","year":"2018","journal-title":"Cell Metabolism"},{"issue":"5","key":"10.1016\/j.molmet.2021.101410_bib37","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmet.2021.101410_bib38","first-page":"1","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","author":"Lagadinou","year":"2013","journal-title":"Stem Cells"},{"issue":"5","key":"10.1016\/j.molmet.2021.101410_bib39","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccr.2011.10.015","article-title":"Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia","volume":"20","author":"\u0160krti\u0107","year":"2011","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.molmet.2021.101410_bib40","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nature Medicine"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877821002684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877821002684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:26:11Z","timestamp":1761956771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877821002684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":40,"alternative-id":["S2212877821002684"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2021.101410","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2021.101410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"101410"}}